BioSpace News Archive

Pharm Country

BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

BioAegis Therapeutics, Inc. announces that it will host a free webinar on the expanding spectrum of auto- and hyper- inflammatory diseases on Tuesday, May 23, 2023 at 2:00 pm Eastern Time.

May 10, 2023
·
5 min read
Drug Development

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics today announced the first participant in Australia has been treated in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

May 10, 2023
·
6 min read
Pharm Country

Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference

Verrica Pharmaceuticals Inc. today announced that Ted White, Verrica President & Chief Executive Officer, will present at the upcoming RBC Capital Markets Global Healthcare Conference, which is being held at the InterContinental New York Barclay Hotel from May 16-17, 2023.

May 10, 2023
·
1 min read
Zevra Therapeutics will Participate in RBC Capital Markets Global Healthcare Conference on May 16, 2023

Zevra Therapeutics, Inc. today announced that R. LaDuane Clifton, the Company’s Chief Financial Officer, will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 16, 2023, at 3:05 p.m. ET.

May 10, 2023
·
2 min read
BioForest

Avalyn Pharma Presenting at BioEquity Europe

Avalyn Pharma Inc. today announced that Lyn Baranowski , CEO, is planning to present a corporate update during the BioEquity Europe conference being held May 14-16, 2023.

May 10, 2023
·
1 min read
Drug Development

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

G1 Therapeutics, Inc. today presented preliminary results from 30 patients enrolled in its ongoing Phase 2, single arm study of trilaciclib administered prior to the antibody-drug conjugate (ADC), sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).

May 10, 2023
·
10 min read
Business

Syros Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Syros Pharmaceuticals today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.

May 10, 2023
·
8 min read
Business

KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer

KBI Biopharma Appoints Marykay Marchigiani as Chief Financial Officer and Sigma Mostafa, Ph.D., as Chief Scientific Officer.

May 10, 2023
·
4 min read
Drug Development

FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of Second Cohort

FSD Pharma Inc. today announced the completion of dosing the first cohort of patients in the Company’s Phase I clinical trial of Lucid-21-302 (“Lucid-MS”).

May 10, 2023
·
7 min read
Biotech Beach

Capsida Biotherapeutics to Present New Data Showing Increased Capsid Expression in CNS at American Society of Gene & Cell Therapy 26th Annual Meeting

Capsida Biotherapeutics (“Capsida”) today announced it will present preliminary data on the company’s next-generation engineered adeno-associated virus (AAV) capsids in non-human primates.

May 10, 2023
·
4 min read